Background BRAF mutations are common in melanoma, with more than 50% harboring activating BRAF mutations. Though BRAF inhibitors are highly efficacious for nearly half of patients with this BRAF-mutant melanoma, many developing secondary resistance...
Background: While hematopoietic stem cell transplantation (HSCT) is an effective treatment for hematological malignancies, it is associated with several potential complications. Recent studies have associated beta-blocker (BB) use in critical care...